دورية أكاديمية

Second IVIg course in Guillain-Barré syndrome with poor prognosis. The non-randomised ISID study

التفاصيل البيبلوغرافية
العنوان: Second IVIg course in Guillain-Barré syndrome with poor prognosis. The non-randomised ISID study
المؤلفون: Verboon C., Van Den Berg B., Cornblath D. R., Venema E., Gorson K. C., Lunn M. P., Lingsma H., Van Den Bergh P., Harbo T., Bateman K., Pereon Y., Sindrup So. H., Kusunoki S., Miller J., Islam Z., Hartung H. -P., Chavada G., Jacobs B. C., Hughes R. A. C., Van Doorn P. A. J. M. Addington, MD (University of Virginia, Charlottesville USA), S. Consortia. Protected by copyright. on October 7, 2019 at Uppsala Universitet BIBSAM http://jnnpTest. bmj. com/ J Neurol Neurosurg Psychiatry: first published as 10. 1136/jnnp-2019-321496 on 5 October 2019. Downloaded from 8 Verboon C, J Neurol Neurosurg Psychiatry 2019, 0:1–9. doi:10. 1136/jnnp-2019-321496 Neuromuscular Ajroud-Driss, MD (Northwestern University Feinberg, Chicago USA), G. Antonini, MD (Mental Health and Sensory Organs (NESMOS), Sapienza University, Sant’Andrea Hospital, Rome Italy), S. Attarian, MD, PhD (CHU Timone, Marseille France), F. A. Barroso, MD (Instituto de Investigaciones Neurológicas Raúl Carrea, FLENI, Buenos Aires, Argentina), L. Benedetti, PhD (Ospedale Sant’ Andrea La Spezia, La Spezia, Italy), T. E. Bertorini, MD (The University of Tennessee Health Science Center (UTHSC), Memphis USA), T. H. Brannagan, MD (Columbia University, New York City, USA), C. Briani, MD (University of Padova, Padova Italy), R. Bhavaraju-Sanka, MD (University Hospital/University of Texas Health Science Center, San Antonio Texas, S. Butterworth, MD (Pinderfields Hospital, Wakefield UK), C. Casasnovas, PhD (Bellvitge University Hospital – IDIBELL Neurometabolic Diseases Group. CIBERER, Barcelona Spain), G. Cavaletti, MD (University Milano-Bicocca, Monza Italy), S. Chen, PhD (Rutgers, Robert Wood Johnson University Hospital, New Brunswick, K. G. Claeys, PhD (1. University Hospitals Leuven, Leuven Belgium, 2. KU Leuven, Leuven Belgium), J. S. Cosgrove, MD (Leeds General Infirmary, Leeds UK), A. Davidson, MD (University of Glasgow, Glasgow UK), E. Dardiotis, MD (University of Thessaly, Hospital of Larissa, Larissa Greece), C. Dornonville de la Cour, MD (National Hospital Copenhagen, Copenhagen Denmark), C. G. Faber, PhD (Maastricht University Medical Centre, Maastricht, The Netherlands), T. E. Feasby, MD (University of Calgary, Calgary Canada), T. Fujioka, MD (Toho University Medical Center, Tokyo Japan), G. Galassi, MD (University Hospital of Modena, Modena Italy), J. M. Gilchrist, MD (Soulthern Illinois University School of Medicine, Springfield USA), N. A. Goyal, MD (University of California, Irvine USA), V. Granit, MD (Montefiore Medical, Center, New York, G. Gutiérrez-Gutiérrez, MD (Hospital Universitario Infanta Sofia, San Sebastian, Spain), R. D. M. Hadden, PhD (King’s College Hospital, London UK), J. K. L. Holt, PhD, FRCP (The Walton Centre, Liverpool UK), M. Htut, MD (St. George’s Hospital, I. Jericó Pascual, PhD (Complejo Hospitalario de Navarra, Pamplona Spain), S. Karafiath, MD (University of Utah School of Medicine, Salt Lake City, H. D. Katzberg, MD (University of Toronto, Toronto Canada), L. Kiers, MD (University of Melbourne, Royal Melbourne Hospital, Parkville Australia), B. C. Kieseier, MD (Heinrich Heine University, Düsseldorf Germany), K. Kimpinski, MD (University Hospital, LHSC London-Ontario, Canada), S. Kuwabara, PhD (Chiba University, Chiba Japan), J. Y. Kwan, MD (University of Maryland School of Medicine, Baltimore USA), S. S. Ladha, MD (Barrow Neurology Clinics, Phoenix Arizona, V. Lawson, MD (Wexner Medical Center at The Ohio State University, Columbus USA), H. Lehmann, PhD (University Hospital of Cologne, Universitätsklinikum Köln, Cologne Germany), H. Manji, FRCP (Ipswich Hospital, Ipswich UK), G. A. Marfia, MD (Neurological Clinic, Policlinico Tor Vergata, C. Márquez Infante, MD (Hospital Universitario Virgen del Rocio, Seville Spain), M. G. Mattiazzi, MD (Hospital Militar Central, C. J. McDermott, MD (Royal Hallamshire Hospital, NIHR Clinical, Sheffield UK), M. S. Monges, MD (Hospital de Pediatría J. P. Garrahan, G. Morís de la Tassa, MD (Hospital Universitario Central de Asturias, Asturias Spain), C. Nascimbene, PhD (Luigi Sacco Hospital, Milan Italy), E. Nobile Orazio, PhD (Milan University, Humanitas Clinicala and Research Institute Milan, R. J. Nowak, MD (Yale University School of Medicine, New Haven, M. Osei-Bonsu (James Cook University Hospital, Middlesbrough UK), J. Pardo Fernandez (Hospital Clínico de Santiago, Santiago de Compostela (A Coruña), L. Querol Gutierrez, PhD (Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, R. Reisin (Hospital Britanico, S. Rinaldi, MBChB, PhD (University of Oxford R. C. Roberts, MD (Addenbrooke’s Hospital Cambridge, Cambridge UK), I. Rojas-Marcos, MD (Hospital Univesitario Reina Sofia, Cordoba Spain), S. A. Rudnicki, MD (University of Arkansas, Fayetteville USA), A. Schenone, PhD (1. Department of Neurosciences, Rehabilitation Ophthalmology, Genetics and Maternal and Infantile Sciences (DINOGMI), University of Genova, Genova, Italy 2. IRCCS Policlinico San Martino, Genova Italy), M. J. Sedano Tous, MD (Hospital Universitario Marques de Valdecilla, Santander Cantabria, N. Shahrizaila, MD (Neurology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Malaya), K. Sheikh, PhD (The University of Texas Health Science Center at Houston, Houston USA), N. J. Silvestri, MD (Buffalo General Medical Center, Buffalo NY, C. L. Sommer, MD (Universitätsklinikum Würzburg, Würzburg Germany), J. D. Varrato, DO (Lehigh Valley Health Network, Allentown USA), J. Verschuuren, PhD (Leiden University Medical Centre, Leiden, M. V. Vytopil, PhD (Tufts University School of Medicine Lahey Hospital W. Waheed, MD (University of Vermont Medical Center, Burlington USA), L. Zhou, PhD (Icahn School of Medicine at Mount Sinai, USA). Other collaborators were:U. A. Badrising, I. R. Bella, MD (University of Mass Medical School, Worcester USA), C. Bunschoten, PhD candidate (Erasmus University Medical Centre, Rotterdam, J. Bürmann, Universitätsklinikum des Saarlandes, Homburg Germany), M. Busby, Bradford UK), C. C. Chao, PhD (National Taiwan University Hospital, Taipei Taiwan), M. E. Conti, MD (University Hospital Clinicas, M. C. Dalakas, MD (1. Thomas Jefferson University, Philadelphia USA, 2. National and Kapodistrian University of Athens, Athens Greece), P. Van Damme, PhD (University Hospital Leuven, A. Doets, the Netherlands), G. W. van Dijk, MD (Canisius Wilhelmina Hospital, Nijmegen, M. M. Dimachkie, MD (University of Kansas Medical Center, Kansas City, K. Doppler, A. Echaniz-Laguna, MD (Hopital de Hautepierre, Strasbourgh France), F. Eftimov, PhD (Amsterdam University Medical Centre, Amsterdam, R. Fazio, MD (Scientific Institute San Raffaele, C. Fokke, MD (Gelre Hospital, Zutphen and Apeldoorn, E. A. Fulgenzi, MD (Hospital Cesar Milstein Buenos Aires, M. P. J. Garssen, PhD (Jeroen Bosch Hospital, ’s Hertogenbosch, Zaltbommel and Drunen, C. J. Gijsbers, MD (Vlietland Hospital, Schiedam, J. Gilhuis, PhD (Reinier de Graaf Gasthuis, Delft, A. Grapperon, MD (CHU Timone, S. T. Hsieh, I. Illa, B. Islam, PhD (International Centre for Diarrhoeal Disease Research, Bangladesh (icddr, b) Dhaka, Bangladesh), K. Jellema, PhD (Haaglanden Medisch Centrum, The Hague, K. Kaida, PhD (National Defense Medical College, Saitama Japan), N. Kokubun, MD (Dokkyo Medical University, Tochigi Japan), N. Kolb, MD (University of Vermont, Burlington VT, R. van Koningsveld, PhD (Elkerliek Hospital, Helmond and Deurne, A. J. van der Kooi, K. Kuitwaard, PhD (Albert Schweitzer Hospital, Dordrecht, L. Landschoff Lassen, MD (Glostrup Hospital, Glostrup Denmark), S. E. Leonhard, M. Mandarakas, PhD (Erasmus University Medical Centre, E. Martinez Hernandez, MD (Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic, Q. D. Mohammad, PhD (National Institute of Neurosciences and Hospital, Dhaka Bangladesh), M. Pulley, MD (University of Florida, Jacksonville USA), Y. A. Rajabally, PhD (Queen Elizabeth Hospital, Birmingham UK), S. W. Reddel, PhD (Concord Repatriation General Hospital, Sydney Australia), T. van der Ree, MD (Westfriesgasthuis, Hoorn, J. Roodbol, G. M. Sachs, MD (University of Rhode Island, Providence USA), J. P. A. Samijn, PhD (Maasstad Hospital, L. Santoro, PhD (University Federico II, Napels Italy), B. Stein, MD (St. Joseph’s Regional Medical Center, Paterson USA), F. H. Vermeij, MD (Franciscus Gasthuis, L. H. Visser, PhD (Elisabeth-TweeSteden Hospital, Tilburg and Waalwijk, H. J. Willison, PhD (University of Glasgow, P. Wirtz, PhD (HagaZiekenhuis, S. A. Zivkovich, PhD (University of Pittsburgh Medical Center, Pittsburgh USA).
المساهمون: C., Verboon, B., Van Den Berg, D. R., Cornblath, E., Venema, K. C., Gorson, M. P., Lunn, H., Lingsma, P., Van Den Bergh, T., Harbo, K., Bateman, Y., Pereon, So. H., Sindrup, S., Kusunoki, J., Miller, Z., Islam, H. -P., Hartung, G., Chavada, B. C., Jacob, R. A. C., Hughe, Addington, Van Doorn P. A. J. M., (University of Virginia, Md, USA), Charlottesville, on October 7, S. Consortia. Protected by copyright., Downloaded from 8 Verboon C, 2019 at Uppsala Universitet BIBSAM http://jnnpTest. bmj. com/ J Neurol Neurosurg Psychiatry: first published as 10. 1136/jnnp-2019-321496 on 5 October 2019., J Neurol Neurosurg Psychiatry 2019, 1136/jnnp-2019-321496 Neuromuscular Ajroud-Driss, 0:1–9. doi:10., (Northwestern University Feinberg, Md, USA), Chicago, Antonini, G., (Mental Health and Sensory Organs (NESMOS), Md, University, Sapienza, Hospital, Sant’Andrea, Italy), Rome, Attarian, S., Md, (CHU Timone, Phd, France), Marseille, Barroso, F. A., (Instituto de Investigaciones Neurológicas Raúl Carrea, Md, Fleni, Aires, Bueno, Argentina), Benedetti, L., (Ospedale Sant’ Andrea La Spezia, Phd, Spezia, La, Italy), Bertorini, T. E., (The University of Tennessee Health Science Center (UTHSC), Md, USA), Memphi, Brannagan, T. H., (Columbia University, Md, York City, New, USA), Briani, C., (University of Padova, Md, Italy), Padova, Bhavaraju-Sanka, R., (University Hospital/University of Texas Health Science Center, Md, Antonio Texas, San, Butterworth, S., (Pinderfields Hospital, Md, UK), Wakefield, Casasnovas, C., Ciberer, PhD (Bellvitge University Hospital – IDIBELL Neurometabolic Diseases Group., Spain), Barcelona, Cavaletti, G., (University Milano-Bicocca, Md, Italy), Monza, Chen, S., (Rutgers, Phd, Wood Johnson University Hospital, Robert, Brunswick, New, Claeys, K. G., University Hospitals Leuven, PhD (1., Belgium, Leuven, KU Leuven, 2., Belgium), Leuven, Cosgrove, J. S., (Leeds General Infirmary, Md, UK), Leed, Davidson, A., (University of Glasgow, Md, UK), Glasgow, Dardiotis, E., (University of Thessaly, Md, of Larissa, Hospital, Greece), Larissa, Dornonville de la Cour, C., (National Hospital Copenhagen, Md, Denmark), Copenhagen, Faber, C. G., (Maastricht University Medical Centre, Phd, Maastricht
بيانات النشر: BMJ Publishing Group
BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
سنة النشر: 2020
المجموعة: Sapienza Università di Roma: CINECA IRIS
مصطلحات موضوعية: guillain-barré syndrome, poor prognosi, second ivig course, treatment, adult, aged, disability evaluation, female, guillain-barre syndrome, human, immunoglobulin g, immunoglobulin, intravenou, immunologic factor, male, middle aged, prognosi, time factor, treatment outcome, drug administration schedule
الوصف: Objective To compare disease course in patients with Guillain-Barré syndrome (GBS) with a poor prognosis who were treated with one or with two intravenous immunoglobulin (IVIg) courses. Methods From the International GBS Outcome Study, we selected patients whose modified Erasmus GBS Outcome Score at week 1 predicted a poor prognosis. We compared those treated with one IVIg course to those treated with two IVIg courses. The primary endpoint, the GBS disability scale at 4 weeks, was assessed with multivariable ordinal regression. Results Of 237 eligible patients, 199 patients received a single IVIg course. Twenty patients received an α early' second IVIg course (1-2 weeks after start of the first IVIg course) and 18 patients a α late' second IVIg course (2-4 weeks after start of IVIg). At baseline and 1 week, those receiving two IVIg courses were more disabled than those receiving one course. Compared with the one course group, the adjusted OR for a better GBS disability score at 4 weeks was 0.70 (95%CI 0.16 to 3.04) for the early group and 0.66 (95%CI 0.18 to 2.50) for the late group. The secondary endpoints were not in favour of a second IVIg course. Conclusions This observational study did not show better outcomes after a second IVIg course in GBS with poor prognosis. The study was limited by small numbers and baseline imbalances. Lack of improvement was likely an incentive to start a second IVIg course. A prospective randomised trial is needed to evaluate whether a second IVIg course improves outcome in GBS.
نوع الوثيقة: article in journal/newspaper
اللغة: English
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31586949; info:eu-repo/semantics/altIdentifier/wos/WOS:000508888700002; volume:91; issue:2; firstpage:1; lastpage:9; numberofpages:9; journal:JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY; http://hdl.handle.net/11573/1509595Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85073171517
DOI: 10.1136/jnnp-2019-321496
الإتاحة: https://doi.org/10.1136/jnnp-2019-321496Test
http://hdl.handle.net/11573/1509595Test
حقوق: info:eu-repo/semantics/closedAccess
رقم الانضمام: edsbas.482A9034
قاعدة البيانات: BASE